World Orphan Drug Congress USA focuses on the most pressing challenges and opportunities to bring rare disease therapies to patients faster.
A global gathering of 1,500 leaders in orphan drugs from 50 countries online. World Orphan Drug Congress USA will feature over 260 presentations covering all aspects of orphan drug development and rare disease research.
Aenova’s dedication to pharmaceutical development goes back over 120 years to the late 19th century. We are proud to use our experience in the application of sound science which ultimately contributes to a better life for patients suffering from rare diseases.
Our pharmaceutical development services include:
Formulation and process development
Analytical development and validation
ICH stability studies
Regulatory support for submission or post-authorization changes
Clinical trial management and preparation of clinical trial supply
Design of primary and secondary packaging configurations
The Aenova Group is one of the world’s largest providers of services covering the entire value chain for the development and production of all main dosage forms in the field of pharmaceuticals and dietary supplements. As a leading CDMO, the Aenova Group focuses on high standards of quality, innovative technologies and a clear vision for the future.